FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385873474> ?p ?o ?g. }

• W4385873474 abstract "<p><i>In vitro</i> functional characteristics of antihuman ICOS agonist mAb feladilimab. <b>A,</b> Detection of ICOS on naïve or preactivated (48 hours anti-CD3/CD28) peripheral blood T cells from healthy human donors using feladilimab (3 μg/mL, soluble) and subsequent FITC-conjugated anti-human IgG secondary antibody. Each symbol represents an individual donor. See <a href=#SMF1 target=_blank>Supplementary Fig. S1</a> for flow cytometry gating strategy. Confocal microscopy illustrating kinetics of ICOS cellular localization using feladilimab (3 μg/mL, soluble) as the antibody for staining (<b>B</b>) and T cell–DC interactions following coincubation with feladilimab and CD3/CD28 (<b>C</b>). <b>C,</b> Stimulated T cells exhibit ICOS polarization and mobilization toward neighboring DCs (dark), localizing with related costimulatory receptor CD28; (I–III) denote image overlays, with (IV) combining all markers. <b>D,</b> Representative Western blot analyses of AKT pathway phosphorylation in activated CD4⁺ T cells following treatment with soluble feladilimab or isotype control (1 and 10 μg/mL, soluble) for 0–24 hours; uncropped images available in <a href=#SMF12 target=_blank>Supplementary Fig. S12A</a>. As illustrated in <b>E</b>, CD4⁺ non-T_reg (CD4⁺ CD25⁻) and T_reg cells (CD4⁺ CD25⁺ CD127_low) were isolated from healthy donor peripheral blood and stimulated using plate-bound anti-CD3 (1 μg/mL) ± feladilimab or isotype control (each at 5 μg/mL) for 72 hours. <b>F,</b> RNA-based analysis (Nanostring) of T_reg-associated marker (<i>FOXP3</i>, <i>ICOS</i>, <i>TIGIT</i>, and <i>CTLA4</i>) expression by the stimulated cell subsets (each symbol represents an individual donor). <b>G,</b> Cytokine-based analysis of T-cell subsets following stimulation with plate-bound anti-CD3 and a dose range of feladilimab or isotype control; see <a href=#SMF1 target=_blank>Supplementary Fig. S1</a> for gating strategy. <b>H,</b> IFNγ production in the supernatant of PBMC cultures from patients with NSCLC following plate-bound feladilimab and anti-CD3 (0.6 μg/mL) stimulation (24 and 48 hours for healthy donors; 72 hours for patients with NSCLC). Data in A and H represent the mean ± s.e.m; significance determined by unpaired Student <i>t</i> test. Where shown, significance was determined by one-way ANOVA. AKT, protein kinase B; Fc, fragment crystallizable; ANOVA, analysis of variance; DC, dendritic cell; ICOS, inducible T cell costimulator; IFN, interferon; Ig, immunoglobulin; mAB, monoclonal antibody; NSCLC, non–small cell lung carcinoma; PBMC, peripheral blood mononuclear cells; s.e.m., standard error of the mean.</p>" @default.
• W4385873474 created "2023-08-17" @default.
• W4385873474 creator A5000219610 @default.
• W4385873474 creator A5001962000 @default.
• W4385873474 creator A5004021303 @default.
• W4385873474 creator A5004072228 @default.
• W4385873474 creator A5015114773 @default.
• W4385873474 creator A5015668076 @default.
• W4385873474 creator A5018536695 @default.
• W4385873474 creator A5022516918 @default.
• W4385873474 creator A5026700573 @default.
• W4385873474 creator A5027408575 @default.
• W4385873474 creator A5027768129 @default.
• W4385873474 creator A5029679351 @default.
• W4385873474 creator A5038356599 @default.
• W4385873474 creator A5038887077 @default.
• W4385873474 creator A5039345673 @default.
• W4385873474 creator A5045119909 @default.
• W4385873474 creator A5046901107 @default.
• W4385873474 creator A5049176429 @default.
• W4385873474 creator A5053416448 @default.
• W4385873474 creator A5059006181 @default.
• W4385873474 creator A5059747154 @default.
• W4385873474 creator A5060469120 @default.
• W4385873474 creator A5060590115 @default.
• W4385873474 creator A5062799755 @default.
• W4385873474 creator A5062921585 @default.
• W4385873474 creator A5063142060 @default.
• W4385873474 creator A5069580658 @default.
• W4385873474 creator A5073127295 @default.
• W4385873474 creator A5076409863 @default.
• W4385873474 creator A5085886223 @default.
• W4385873474 creator A5086481435 @default.
• W4385873474 creator A5088225387 @default.
• W4385873474 creator A5092500863 @default.
• W4385873474 creator A5092502012 @default.
• W4385873474 creator A5092502033 @default.
• W4385873474 date "2023-08-16" @default.
• W4385873474 modified "2023-09-27" @default.
• W4385873474 title "FIGURE 2 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade" @default.
• W4385873474 doi "https://doi.org/10.1158/2767-9764.23968508.v1" @default.
• W4385873474 hasPublicationYear "2023" @default.
• W4385873474 type Work @default.
• W4385873474 citedByCount "0" @default.
• W4385873474 crossrefType "posted-content" @default.
• W4385873474 hasAuthorship W4385873474A5000219610 @default.
• W4385873474 hasAuthorship W4385873474A5001962000 @default.
• W4385873474 hasAuthorship W4385873474A5004021303 @default.
• W4385873474 hasAuthorship W4385873474A5004072228 @default.
• W4385873474 hasAuthorship W4385873474A5015114773 @default.
• W4385873474 hasAuthorship W4385873474A5015668076 @default.
• W4385873474 hasAuthorship W4385873474A5018536695 @default.
• W4385873474 hasAuthorship W4385873474A5022516918 @default.
• W4385873474 hasAuthorship W4385873474A5026700573 @default.
• W4385873474 hasAuthorship W4385873474A5027408575 @default.
• W4385873474 hasAuthorship W4385873474A5027768129 @default.
• W4385873474 hasAuthorship W4385873474A5029679351 @default.
• W4385873474 hasAuthorship W4385873474A5038356599 @default.
• W4385873474 hasAuthorship W4385873474A5038887077 @default.
• W4385873474 hasAuthorship W4385873474A5039345673 @default.
• W4385873474 hasAuthorship W4385873474A5045119909 @default.
• W4385873474 hasAuthorship W4385873474A5046901107 @default.
• W4385873474 hasAuthorship W4385873474A5049176429 @default.
• W4385873474 hasAuthorship W4385873474A5053416448 @default.
• W4385873474 hasAuthorship W4385873474A5059006181 @default.
• W4385873474 hasAuthorship W4385873474A5059747154 @default.
• W4385873474 hasAuthorship W4385873474A5060469120 @default.
• W4385873474 hasAuthorship W4385873474A5060590115 @default.
• W4385873474 hasAuthorship W4385873474A5062799755 @default.
• W4385873474 hasAuthorship W4385873474A5062921585 @default.
• W4385873474 hasAuthorship W4385873474A5063142060 @default.
• W4385873474 hasAuthorship W4385873474A5069580658 @default.
• W4385873474 hasAuthorship W4385873474A5073127295 @default.
• W4385873474 hasAuthorship W4385873474A5076409863 @default.
• W4385873474 hasAuthorship W4385873474A5085886223 @default.
• W4385873474 hasAuthorship W4385873474A5086481435 @default.
• W4385873474 hasAuthorship W4385873474A5088225387 @default.
• W4385873474 hasAuthorship W4385873474A5092500863 @default.
• W4385873474 hasAuthorship W4385873474A5092502012 @default.
• W4385873474 hasAuthorship W4385873474A5092502033 @default.
• W4385873474 hasBestOaLocation W43858734741 @default.
• W4385873474 hasConcept C104317684 @default.
• W4385873474 hasConcept C148125776 @default.
• W4385873474 hasConcept C153911025 @default.
• W4385873474 hasConcept C154317977 @default.
• W4385873474 hasConcept C159654299 @default.
• W4385873474 hasConcept C185592680 @default.
• W4385873474 hasConcept C202751555 @default.
• W4385873474 hasConcept C203014093 @default.
• W4385873474 hasConcept C2776090121 @default.
• W4385873474 hasConcept C2776415932 @default.
• W4385873474 hasConcept C2778453870 @default.
• W4385873474 hasConcept C553184892 @default.
• W4385873474 hasConcept C55493867 @default.
• W4385873474 hasConcept C86803240 @default.
• W4385873474 hasConcept C8891405 @default.
• W4385873474 hasConceptScore W4385873474C104317684 @default.
• W4385873474 hasConceptScore W4385873474C148125776 @default.
• W4385873474 hasConceptScore W4385873474C153911025 @default.
• W4385873474 hasConceptScore W4385873474C154317977 @default.

• next